NSCLC patients at stage IV received the PD-1 inhibitor nivolumab in the second line and pembrolizumab in the first line, had up to 16% and 31.9% of patients living for five years, respectively [117,143]. Here, RPL17 is linked to non-small cell lung carcinoma.